Nox Health, a global sleep health leader has acquired Somryst, an FDA-cleared Prescription Digital Therapeutic (PDT) for chronic insomnia.
This acquisition strengthens Nox's value-based healthcare programs and underscores the significance of sleep in managing chronic health conditions. Somryst delivers effective treatment for adults with chronic insomnia through a mobile application, providing a novel solution for those lacking access to therapist-delivered cognitive behavioural therapy for insomnia (CBT-I).
Clinical studies have shown that Somryst significantly improves insomnia symptoms, with over 40% of patients no longer meeting the criteria for chronic insomnia post-treatment. Nox plans to introduce Somryst to a wider audience, starting with its existing client base, marking a significant milestone in its growth journey.
Nox Health aims to revolutionise sleep healthcare using data, science, technology, and compassionate care, focusing on accurate sleep diagnostics, comprehensive sleep care management, and outcomes measurement to improve the health of individuals suffering from chronic conditions.
Click here to read the original news story.